Cardiol Omicron As Omicron spreads like wildfire and hospitalizations increase, it is highly likely Cardiol Rx will be fast tracked. Retail investors have short memories but this is going to be huge: "High-risk patients with Cardiovascular Disease (CVD), hospitalized with COVID-19 CardiolRx Cardiol has received approval from the U.S. Food and Drug Administration for its Investigational New Drug application to conduct a Phase II/III clinical trial investigating the efficacy and safety of CardiolRx in the treatment of hospitalized COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease".